Clinical trial NCT04192474: Evaluation of Performance and Safety of Ambu® aScope™ 4 Cysto and aView™ Urologia for Flexible Cystoscopy
Official title: Clinical Investigation to Evaluate the Performance and Safety of Ambu® aScope™ 4 Cysto and aView™ Urologia for Flexible Cystoscopy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cystoscope
Lower Urinary Tract Symptoms
Bladder Disease
Lead sponsor: Ambu A/S
Sponsor class: INDUSTRY
Collaborators: name: QserveCRO
First posted: 2019-12-10
Enrollment: 83
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: A prospective, multicenter, single- arm open-label clinical study on the performance and safety

* 50% of the patients undergo flexible diagnostic cystoscopy
* 50% of the patients undergo flexible cystoscopy intervention with endoscopic accessories
Primary purpose: OTHER

Brief summary: In this study, the new aScope 4 Cysto is used to see if this new single use, flexible cystoscope performs as well as other routinely used flexible cystoscopes. This study will be done in patients who come to the clinic for either a diagnosis of their urethra and bladder or for a small intervention. For an intervention a lesion or tumor is resected, a stent in the ureter is taken out, or an injection in the bladder wall is given. The flexible cystoscope is passed into the urethra and bladder for visual inspection of the bladder and urethra. It will give information on how well the structures of the urinary tract and bladder can be viewed including any abnormalities that are present. If an intervention is performed the aScope 4 Cysto will be used with an endoscopic accessory.

Detailed description: Clinical Phase: pre-CE study

Design: A prospective, multicenter, single- arm open-label clinical study on the performance and safety of Ambu® aScope™ 4 Cysto and aView™ Urologia, a single-use, flexible cystoscope for flexible cystoscopy

Population: Adult subjects (≥ 18 years) undergoing flexible cystoscopy for diagnostic or therapeutic purposes.

Planned Sample Size: A total of 80 patients will result in a maximum (if the true proportion is 50 %) width (i.e. the difference between the point estimate and the upper, or lower, limit of the confidence interval) of the two-sided 95 % confidence interval for the binary variable "Performance level acceptable" to be 11%. This width is considered to be useful in the interpretations of the results from this part of the trial.

Study duration: Screening, procedure and follow-up will take 14 days maximum. A follow-up telephone call at 7 days post procedure is performed to record any adverse events post-procedure.

Planned Trial Period: 3 months

Investigational Device: Ambu® aScope™ 4 Cysto and aView™ Urologia. A pre-CE, single use cystoscope.

Eligibility criteria: Inclusion Criteria:

* Adults (males and females), ≥18 years of age or older, presenting for cystoscopy
* Ambulatory with a need to undergo cystoscopy for diagnostic or therapeutic purposes
* Willing to participate in a clinical trial

Exclusion Criteria:

* History of high-grade bladder cancer or carcinoma-in-situ of the bladder, undergoing cystoscopy for follow-up/surveillance purposes
* History of prior bladder/urethral reconstructive surgery
* Presence of symptomatic urinary tract infection (UTI)
* Known unpassable urethral stricture
* Unable to read and/or understand the study requirements
* Unable or unwilling to provide consent to participation in the study
* Pregnant or lactating women

Primary outcomes:
measure: Performance of the cystoscope
timeFrame: follow up immediately after procedure
Secondary outcomes:
measure: Overall performance
timeFrame: follow up immediately after procedure
measure: Procedure time
timeFrame: follow up immediately after procedure
measure: Patient Tolerance
timeFrame: follow up immediately after procedure
measure: Adverse events
timeFrame: follow up immediately after procedure
measure: Adverse events
timeFrame: follow-up at 7 days after procedure
Other outcomes:
Locations:
city: Herlev
country: Denmark
facility: Herlev Hospital
city: Rotterdam
country: Netherlands
facility: Erasmus MC
Study officials:
References: